share_log

Virpax Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Virpax Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Virpax製藥 | S-1：證券上市註冊聲明
美股SEC公告 ·  07/29 16:37

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024, for a proposed public offering of its common stock and pre-funded warrants. The offering includes an undisclosed number of shares and pre-funded warrants, with each warrant exercisable for one share of common stock at an exercise price of $0.00001 per share. The warrants are immediately exercisable and may be exercised at any time until fully exercised. RBW Capital Partners LLC, acting through Dominari Securities LLC, has been engaged as the exclusive placement agent for the offering on a reasonable best-efforts basis. The offering is expected to close one business day following its commencement. Virpax intends to use the net proceeds from the offering to fund ongoing activities related to their planned Investigational New Drug (IND) filing for Probudur, as well as for working capital and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'.
Virpax藥品公司（Virpax）是一家處於臨床前階段的藥品公司，於2024年7月29日向美國證券交易委員會（SEC）提交了一份註冊聲明，擬公開發行普通股和預先融資認股權證書。發行包括一定量的股份和預先融資認股權證書，每個證書的行權價格爲每股0.00001美元。認股權證書立即行權，且可以在完全行權之前的任何時間行使。RBW Capital Partners LLC通過Dominari Securities LLC作爲獨家配售代理，在合理的最大努力基礎上開展配售業務。發行預計將於開始後一個營業日結束。Virpax打算利用公開發行的淨收益來資助其有關Probudur新藥申請臨床試驗許可（IND）的持續活動，以及用於營運資本和其他一般企業目的。該公司的普通股在納斯達克資本市場上掛牌交易，代碼爲‘VRPX’。
Virpax藥品公司（Virpax）是一家處於臨床前階段的藥品公司，於2024年7月29日向美國證券交易委員會（SEC）提交了一份註冊聲明，擬公開發行普通股和預先融資認股權證書。發行包括一定量的股份和預先融資認股權證書，每個證書的行權價格爲每股0.00001美元。認股權證書立即行權，且可以在完全行權之前的任何時間行使。RBW Capital Partners LLC通過Dominari Securities LLC作爲獨家配售代理，在合理的最大努力基礎上開展配售業務。發行預計將於開始後一個營業日結束。Virpax打算利用公開發行的淨收益來資助其有關Probudur新藥申請臨床試驗許可（IND）的持續活動，以及用於營運資本和其他一般企業目的。該公司的普通股在納斯達克資本市場上掛牌交易，代碼爲‘VRPX’。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間